CCM
EVFM

CAAS Capital Management’s Evofem Biosciences, Inc. Common Stock EVFM Stock Holding History

CAAS Capital Management’s Portfolio EVFM Stock Details EVFM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-155,687
Closed -$4.09M – 1453
2021
Q1 		$4.09M Buy
+155,687
New +$7.08M 0.04% 405
2020
Q3 		– Sell
-28,304
Closed -$1.2M – 651
2020
Q2 		$1.2M Buy
+28,304
New +$1.91M 0.04% 250

Other funds holding EVFM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
FWSM
First Wilshire Securities Management Pasadena, California $444M AUM 42.88% 1-Year Est. Return

CAAS Capital Management's EVFM Position: Q2 2021 in Review

CAAS Capital Management sold out of Evofem Biosciences, Inc. Common Stock (EVFM) in Q2 2021, closing a stake of 155,687 shares — an estimated $4.09M sold.

CAAS Capital Management first reported a position in EVFM in Q2 2020 and held it in 2 quarters. The position peaked at $4.09M in Q1 2021. 81 funds tracked by Wall St. Rank hold EVFM as of Q2 2021.

  • CAAS Capital Management reported no remaining Evofem Biosciences, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • CAAS Capital Management sold 155,687 Evofem Biosciences, Inc. Common Stock shares in Q2 2021, an estimated $4.09M.
  • CAAS Capital Management first reported a position in Evofem Biosciences, Inc. Common Stock in Q2 2020 and held it in 2 quarters.
  • CAAS Capital Management's Evofem Biosciences, Inc. Common Stock position peaked at $4.09M in Q1 2021.
  • 81 funds tracked by Wall St. Rank held Evofem Biosciences, Inc. Common Stock as of Q2 2021.

Based on CAAS Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.